This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

proofread

Drug from cancer chemotherapy helps fight deadly fungal infections

Drug from cancer chemotherapy helps fight deadly fungal infections
Docking of actinomycin D and imatinib in Agd3. (A) Actinomycin D occupies Agd3 catalytic center. (B) Interactions of actinomycin D with Agd3 amino acids. (C) Imatinib in Agd3 catalytic center. (D) Interactions of imatinib with Agd3 amino acids including the catalytic residues His514 and His668. Credit: International Journal of Molecular Sciences (2023). DOI: 10.3390/ijms24031851

There are up to 10,000 fungal spores in every cubic meter of air that can enter our bodies when we breathe them in. Some of these belong to the species Aspergillus fumigatus, a widespread fungus found everywhere in the environment.

In immunocompromised people—for example, after transplantation or severe respiratory illnesses such as influenza or COVID-19—the fungus can enter the lungs and cause aspergillosis. The infection is particularly difficult to treat—especially because the fungus surrounds itself with a . This acts like a kind of glue and enables Aspergillus to take hold in the tissue. In addition, the fungus seals itself off in this way and protects itself against attacks by the immune system and especially against antimycotics, i.e. anti-fungal drugs.

A research team led by Professor Dr. Françoise Routier from the Institute of Clinical Biochemistry at the Hannover Medical School (MHH) has found a way to prevent the formation of such an Aspergillus biofilm with the help of a drug from cancer chemotherapy. The study has been published in the International Journal of Molecular Sciences.

Sugar molecule is important for biofilm formation

Aspergillus fumigatus is an opportunistic fungus that takes advantage of a weakened immune system and can cause diseases of varying severity, from allergies to fatal mycoses. The infection starts in the lungs but can spread through the bloodstream to the brain, heart, liver and kidneys, affecting more than 300,000 people each year. In the , Aspergillus is embedded in a biofilm that forms a barrier against defense cells and antimicrobials.

"One of the main components of this biofilm is a that the fungus produces itself and then transports outside into its immediate environment," explains Professor Routier. There, the sugar molecule is chemically modified by an enzyme called deacetylase Agd3. This step is essential for the fungus to stick to the body tissue. The researchers were able to prove that biotechnologically modified fungi that lacked the enzyme Agd3 could no longer produce a biofilm.

Drug from cancer chemotherapy helps fight deadly fungal infections
Keeping an eye on the Aspergillus biofilm: Professor Dr. Françoise Routier (right) and her research assistant Patricia Zarnovican. Credit: Karin Kaiser / MHH

The biochemist's idea was now to look for a substance that inhibits the enzyme Agd3 and thus prevents the formation of the biofilm. To do this, she used computers to search so-called drug libraries for active substances that are already approved and inhibit precisely this Agd3 activity. In-silico screening is the name of the method in the language of science—and it led to the trace of a drug called imatinib, which is used in chemotherapy.

In cell culture, imatimib was able to significantly reduce the Aspergillus biofilm. Studies on larvae of the butterfly Galleria mellonella also confirmed the effect. The caterpillars of the "great wax moth" serve as a for research into biofilms caused by microorganisms such as fungi or even bacteria. "We infected the larvae with Aspergillus and saw that fewer caterpillars died when treated with the ," says Professor Routier.

Imatinib must lose its effect as a cytotoxin

Before imatinib can be used against biofilms in humans, however, the drug still needs to be chemically modified. "The drug destroys the protective layer of the fungal colony, but as a chemotherapeutic agent it also acts as a cytotoxin, which is undesirable for this application," the biochemist explains. If the cytotoxic effect can be removed without losing the Agd3 , the biofilm destroyer could at least mitigate the problem of increasing resistance to the antimycotics used.

"This gives us great hope for the development of new combination therapies against the ," says Professor Routier.

More information: Carla I. I. Seegers et al, Identification of Compounds Preventing A. fumigatus Biofilm Formation by Inhibition of the Galactosaminogalactan Deacetylase Agd3, International Journal of Molecular Sciences (2023). DOI: 10.3390/ijms24031851

Provided by Medizinische Hochschule Hannover

Citation: Drug from cancer chemotherapy helps fight deadly fungal infections (2023, February 28) retrieved 25 February 2024 from https://phys.org/news/2023-02-drug-cancer-chemotherapy-deadly-fungal.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

New family of enzymes reveals the Achilles' heel of fungal pathogens

228 shares

Feedback to editors